BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharmaconomics//FDA Catalyst Calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
BEGIN:VEVENT
UID:pharmaconomics-533@pharmaconomics
DTSTAMP:20260707T052739Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:SLN Phase 1 — SLN312 (estimated date)
DESCRIPTION:Phase 1 trial results for SLN312 in dyslipidemia are due ~ Dec 31\, 2026. A clean hit validates the program\; a miss can gap the stock down hard.\n\nPrimary source: https://www.sec.gov/Archives/edgar/data/1479615/000119312526279577/sln-ex99_1.htm\n\nTrack it: https://pharmaconomics.com/e/533
URL:https://pharmaconomics.com/e/533
TRANSP:TRANSPARENT
BEGIN:VALARM
TRIGGER:-P1D
ACTION:DISPLAY
DESCRIPTION:SLN catalyst tomorrow
END:VALARM
END:VEVENT
END:VCALENDAR